The present invention relates to heterocyclic compounds of Formula I useful as anti-infective agents. The present invention further relates to a method of treating an infection by administering such compounds, and to pharmaceutical compositions comprising such compounds. ##STR00001##

An energy storage device includes a cathodic material in an activated state; and an anodic material in an activated state; wherein: the cathodic material is covalently attached to, or confined within, a first polymer matrix, the first polymer matrix is configured to prevent or minimize substantial diffusion of the cathodic material in the activated state; and the anodic material is a phenazine, a phenothiazine, a triphenodithiazine, a carbazole, a indolocarbazole, a biscarbazole, or a ferrocene covalently attached to, or confined within, a second polymer matrix, the second polymer matrix is configured to prevent or minimize substantial diffusion of the anodic material in the activated state.

The present invention relates to the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer, more particularly pancreatic cancer. The inventors found a novel family compounds of formula (I) able to treat a variety of cancers by inhibiting NUPR1, a stress-inducible 82-amino-acid-long, intrinsically disordered member of the AT-hook family of chromatin proteins. Thus, the present invention relates to a compound of formula (I) for its use in the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer. In particular, the inventors tested compounds of formula (I) on four well characterized primary pancreatic cancer-derived cells 02.063 and LIPC (Basal subtype), Foic8b (derived from a liver metastasis) and HN14 (Classical subtype), as well as on other cellular lines derived from different tumors, i.e. U87 (glioblastoma), A375 and B16 (melanoma), U20S and SaOS (osteosarcoma), HT29, SK-CO-1 and LS174T (colon cancer), HepG2 (hepatocarcinoma), PC3 (prostate) and MDA-MB-231 (breast cancer). The compounds per se are also claimed.

The present invention relates to the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer, more particularly pancreatic cancer. The inventors found a novel family compounds of formula (I) able to treat a variety of cancers by inhibiting NUPR1, a stress-inducible 82-amino-acid-long, intrinsically disordered member of the AT-hook family of chromatin proteins. Thus, the present invention relates to a compound of formula (I) for its use in the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer. In particular, the inventors tested compounds of formula (I) on four well characterized primary pancreatic cancer-derived cells 02.063 and LIPC (Basal subtype), Foic8b (derived from a liver metastasis) and HN14 (Classical subtype), as well as on other cellular lines derived from different tumors, i.e. U87 (glioblastoma), A375 and B16 (melanoma), U20S and SaOS (osteosarcoma), HT29, SK-CO-1 and LS174T (colon cancer), HepG2 (hepatocarcinoma), PC3 (prostate) and MDA-MB-231 (breast cancer). The compounds per se are also claimed.

The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).

The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).

The present invention discloses a thermally activated delayed fluorescence material and application thereof in an organic electroluminescence device. The thermally activated delayed fluorescence material is a compound having the general structure of Formula I or Formula II: ##STR00001## In Formula I and Formula II, R.sub.1 is a cyano, p is 1, 2 or 3, q is 1, 2 or 3, m is 1 or 2, n is 1 or 2, Ar.sub.1 is a phenyl substituted with one or more groups selected from C.sub.1-6 alkyl, methoxy, ethoxy, or phenyl, Ar.sub.2 and Ar.sub.3 are selected from the following groups: ##STR00002## ##STR00003## ##STR00004## ##STR00005##
and X is bromine or iodine. The present invention further discloses application of the thermally activated delayed fluorescence material as a host material or a luminescent dye of a luminescent layer of an organic electroluminescence device.

The present invention discloses a thermally activated delayed fluorescence material and application thereof in an organic electroluminescence device. The thermally activated delayed fluorescence material is a compound having the general structure of Formula I or Formula II: ##STR00001## In Formula I and Formula II, R.sub.1 is a cyano, p is 1, 2 or 3, q is 1, 2 or 3, m is 1 or 2, n is 1 or 2, Ar.sub.1 is a phenyl substituted with one or more groups selected from C.sub.1-6 alkyl, methoxy, ethoxy, or phenyl, Ar.sub.2 and Ar.sub.3 are selected from the following groups: ##STR00002## ##STR00003## ##STR00004## ##STR00005##
and X is bromine or iodine. The present invention further discloses application of the thermally activated delayed fluorescence material as a host material or a luminescent dye of a luminescent layer of an organic electroluminescence device.

The present invention provides a phenothiazine derivative of formula (I) for use in preventing and/or treating infection caused by bacteria carrying Type IV pili, such as N. meningitidis, and more specifically for use in preventing and/or treating meningitis. The present invention further relates to a composition for the use in preventing and/or treating infection caused by bacteria carrying Type IV pili, such as purpura fulminans and meningitis, comprising a phenothiazine derivative of formula (I) and an antibiotic selected from the group consisting of beta-lactams and aminoglycosides, and/or dexamethasone.

##STR00001##

The present invention relates to substituted benzoxazines and related compounds and derivatives thereof and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.